Tofacitinib (CP-690550) Citrate

Licensed by Pfizer 製品コード:S5001 別名:Tasocitinib Citrate

For research use only.

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.

Tofacitinib (CP-690550) Citrate化学構造

CAS No. 540737-29-9

サイズ 価格(税別)
10mM (1mL in DMSO) JPY 33700
JPY 26400
JPY 80000

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(177)

製品安全説明書

JAK阻害剤の選択性比較

相関JAK製品

生物活性

製品説明 Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.
ターゲット
JAK3 [1]
(Cell-free assay)
JAK2 [4]
(Cell-free assay)
1 nM 20 nM
体外試験

Tofacitinib citrate inhibits IL-2-mediated human T cell blast proliferation and IL-15-induced CD69 expression with IC50 of 11 nM and 48 nM, respectively. Tofacitinib citrate prevents mixed lymphocyte reaction with IC50 of 87 nM. Tofacitinib citrate treatment of murine factor-dependent cell Patersen–erythropoietin receptor (FDCP-EpoR) cells harboring human wild-type or V617F JAK2 leads to prevention of cell proliferation with IC50 of 2.1 µM and 0.25 µM, respectively. Tofacitinib citrate inhibits interleukin-6-induced phosphorylation of STAT1 and STAT3 with IC50 of 23 nM and 77 nM, respectively. Moreover, Tofacitinib citrate generates a significant pro-apoptotic effect on murine FDCP-EpoR cells carrying JAK2VV617F, whereas a lesser effect is observed for cells carrying wild-type JAK2. This activity is coupled with the inhibition of phosphorylation of the key JAK2V617F-dependent downstream signaling effectors signal transducer and activator of transcription (STAT)3, STAT5, and v-akt murine thymoma viral oncogene homolog (AKT). [2] Additionally, Tofacitinib citrate prevents IL-15-induced CD69 expression in human and cynomolgus monkey NK and CD8+ T cells in vitro. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MXTGeY5kfGmxbjDhd5NigQ>? MmHoN|AhdWmwcx?= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC2odYPl[EBLSUt|IHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{Bxd2y7Z3z1eIFucWNiYXPp[E11gXKxc3nu[UBieyC|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhU2liPTCwMlAxODRizszNMi=> NIPSPXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2PFQ5PCd-MkO2Olg1QDR:L3G+
Sf9 MlfuSpVv[3Srb36gZZN{[Xl? MUe5NEBucW6| NEXXdGNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygS3NVNXSjZ3fl[EBLSUt|IHX4dJJme3OnZDDpckBU\jliY3XscJMhfXOrbnegRolwfGmwLVzDMWVSTUSHUFXHSHlHTVeORTDhd{B{fWK|dILheIUh[W[2ZYKgPVAhdWmwczDifUBVWi2IUlXUJIF{e2G7LDDJR|UxKD1iMD6wNFA3KM7:TT6= MnPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOEe3OVAoRjJ{MEi3O|UxRC:jPh?=
Sf9 NWnpeFRxTnWwY4Tpc44h[XO|YYm= NEHJZZQ{OCCvaX7z MmWzTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvZoXz[YQhUkGNMTDjZZRidHm2aXOg[I9u[WmwIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcocheG:ueXfseZRidWmlIHHjbYQufHm{b4PpcoUh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliRVzJV2EtKEurIE2gNE4xODB5IN88UU4> MonKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 NXjIVWxSTnWwY4Tpc44h[XO|YYm= NYmwWFZQOzBibXnudy=> MUDJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC2odYPl[EBLSUt{IHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{Bxd2y7Z3z1eIFucWNiYXPp[E11gXKxc3nu[UBieyC|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhU2liPTCwMlAxODdizszNMi=> MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0PFQoRjJ|Nk[4OFg1RC:jPh?=
Sf9 MWjGeY5kfGmxbjDhd5NigQ>? MnrsTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCJU2SteIFo\2WmIFrINUBld22jaX6gLFc5PSC2b{GxNlUqKG:oIFrBT|Mh\XiycnXzd4VlKGmwIHnud4VkfCCVZkmgZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSByLkCwNUDPxE1w NWLSe3hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
Sf9 NH21WmtHfW6ldHnvckBie3OjeR?= MkfjTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIHj1cYFvKEqDS{OgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMEGg{txONg>? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTFyNUexNUc,OjFzMEW3NVE9N2F-
Sf9 MVXGeY5kfGmxbjDhd5NigQ>? MXO5NEBucW6| NFzmPGVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygS3NVNXSjZ3fl[EBLSUtzIHX4dJJme3OnZDDpckBU\jliY3XscJMhfXOrbnegRolwfGmwLVzDMWVSTUSHUFXHSHlHTVeORTDhd{B{fWK|dILheIUh[W[2ZYKgPVAhdWmwczDifUBVWi2IUlXUJIF{e2G7LDDJR|UxKD1iMD6wNFMh|ryPLh?= M{PVb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
Sf9 NWDiPJZFTnWwY4Tpc44h[XO|YYm= MnfZTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIHj1cYFvKEqDS{OgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMEOzJO69VS5? NEHVd449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
Sf9 MlnDSpVv[3Srb36gZZN{[Xl? MVm5NEBucW6| Mmm2TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgTmFMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEC0JO69VS5? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB6N{e1NEc,OjJyOEe3OVA9N2F-
SF21 MVTGeY5kfGmxbjDhd5NigQ>? NXv1PWRPOTBibXnudy=> MWrJcohq[mm2aX;uJI9nKEqDS{KgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hW0Z{MTDj[YxteyC3c3nu[{BDcW:2aX6tT2FKTVSGS1XZXXRXU0RiYYOgd5Vje3S{YYTlJIFv\CCdM{PQ[4FudWGfQWTQJIlv[3WkYYTl[EBnd3JiMUCgcYlveyCycnnvdkB1dyC|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCWb4Djc5VvfCCjbnHsfZNqeyxiSVO1NEA:KDBwMEC0JO69VS5? M3LLS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUSxOlcxLz5{M{W0NVY4ODxxYU6=
insect cells MojRSpVv[3Srb36gZZN{[Xl? M1\jbGlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDKZYsyKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegO|AhfU1iQWTQMEBKSzVyIE2gNE4xODZzIN88UU4> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF3NU[wOUc,OjFzNUW2NFU9N2F-
insect cells M4n1XmZ2dmO2aX;uJIF{e2G7 MmG4TY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIFrhb|Mh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzCxPEB2VSCDVGCsJGlEPTBiPTCwMlAxQCEQvF2u NH2wVmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG1OVYxPSd-MkGxOVU3ODV:L3G+
T-cells NULLfJk5TnWwY4Tpc44h[XO|YYm= MlT2O|IhcHK| M2nIUmlvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDoeY1idiCWIHPlcIx{KGG|c3Xzd4VlKGG|IGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDh[pRmeiB5MjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvODFzIN88UU4> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
insect NXvL[ldkTnWwY4Tpc44h[XO|YYm= NXH0dJRNUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJGpiczJiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{AzOCC3TTDBWHAtKEmFNUCgQUAxNjBzMjFOwG0v Mkn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW2NFUoRjJzMUW1OlA2RC:jPh?=
MO7 NHfNeZZHfW6ldHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKEqja{OtcYVlcWG2ZXSgTWwyPS2rbnT1Z4VlKFO2YYS1JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNU|ch[2WubIOgZpkh[2WubD3iZZNm\CCjc4PhfUwhUUN3MDC9JFAvODJ2IN88UU4> MkXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNUW2NFUoRjJzMUW1OlA2RC:jPh?=
Ba/F3 MXTGeY5kfGmxbjDhd5NigQ>? NGPVeVI3OCCvaX7z MYXJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCMQVuxJIV5eHKnc4Pl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBi\nSncjC2NEBucW6|IHL5JGFteGijU3Py[YVvKGG|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=> NWTOWVFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
T-cells MnzDSpVv[3Srb36gZZN{[Xl? NI\YUnBKdmirYnn0bY9vKG:oIFrBT|MwOSCrbjDoeY1idiCWIHPlcIx{KGW6cILld5NqdmdiQ1SzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFViKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODJ6IN88UU4> MmDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEC2OFgoRjJ|NUSwOlQ5RC:jPh?=
PBMC M3HuZWZ2dmO2aX;uJIF{e2G7 MlW5TY5pcWKrdHnvckBKVC15LXnu[IN2\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBDVUNiY3XscJMh[nliZnzve{BkgXSxbXX0dpktKEmFNUCgQUAxNjB|OTFOwG0v NYi2ZpNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5Nlc1OjNpPkK2PVI4PDJ|PD;hQi=>
TF1 MYPGeY5kfGmxbjDhd5NigQ>? NFLJ[2czOCCvaX7z MlzXTY5pcWKrdHnvckBw\iCMQVuxJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNPi2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nliSVy2JINp[WyuZX7n[UBnd3JiM{CgcYlveyCrbjDwdoV{\W6lZTDv[kB4cG:uZTDicI9w\CxiRVO1NEA:KDBwMESzJO69VS5? M3zuNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
TF1 NXLB[Ih1TnWwY4Tpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNPi2|dHnteYxifGWmIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBjgSCDbIDoZXNkemWnbjDhd5NigSxiSV7IJF0hOC5yNEWg{txONg>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN5Mk[1N{c,OjZ|N{K2OVM9N2F-
CTLL MmT4SpVv[3Srb36gZZN{[Xl? MY\Jcohq[mm2aX;uJI9nKEqja{OtcYVlcWG2ZXSgTWwzNWmwZIXj[YQhW3SjdEWgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIFPUUGwh[2WubIOgZpkh[2WubD3iZZNm\CCjc4PhfUwhUUN3MDC9JFAvODR6IN88UU4> M2O1[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUW1OlA2Lz5{MUG1OVYxPTxxYU6=
Sf9 M{PtSWZ2dmO2aX;uJIF{e2G7 M1LzblkxKG2rboO= MkPWTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgWHlMOiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJJV{cW6pIFLpc5Rqdi2OQz3FVWVFTVCHR1TZSmVYVEViYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDBwMEWyJO69VS5? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB6N{e1NEc,OjJyOEe3OVA9N2F-
TF1 MlrZSpVv[3Srb36gZZN{[Xl? M2nNfmlvcGmkaYTpc44hd2ZiSlHLNUBqdiCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDJvaX7keYNm\CCVVFHUN{BxcG:|cHjvdplt[XSrb36sJGVEPTBiPTCwMlA2OyEQvF2u NXLEV|NTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PVE1ODJpPkKyOVkyPDB{PD;hQi=>
TF1 M13sR2Z2dmO2aX;uJIF{e2G7 NU\SbodsOjBibXnudy=> MVTJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gWGYyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWw3NWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhOjBibXnud{BxemmxcjD0c{BKVDZvaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDNyIITvJFQ2KG2rboOsJGVEPTBiPTCwMlA2OyEQvF2u NHrJdI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[5PFA5PCd-MkK2PVgxQDR:L3G+
TF1 MmnrSpVv[3Srb36gZZN{[Xl? Mm\ONlAhdWmwcx?= M1zXbGlvcGmkaYTpc44hd2ZiSlHLNUBqdiCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDZvaX7keYNm\CCVVFHUN{BxcG:|cHjvdplt[XSrb36gbY5kfWKjdHXkJIZweiB{MDDtbY5{KG[xbHzve4VlKGK7IFnMOkBkcGGubHXu[4Uh\m:{IEOwJI1qdnNuIFXDOVAhRSByLkC1N{DPxE1w M4nPZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkW5NlE1Lz5{M{[1PVIyPDxxYU6=
Ba/F3 M1LLNWZ2dmO2aX;uJIF{e2G7 MmrUOlAhdWmwcx?= M4PkbGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFrBT|Mh\XiycnXzd4VlKGmwIFLhM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gV3RCXDVicHjvd5Bpd3K7bHH0bY9vKGGodHXyJFYxKG2rboOgZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUAxNjB3NDFOwG0v M2\xTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEi3O|UxLz5{MkC4O|c2ODxxYU6=
T-cells NX7ybJZWTnWwY4Tpc44h[XO|YYm= MWfJcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hdW:wa3X5JHQh[2WubIOgZpkhdWm6ZXSgcJlueGixY4n0[UBz\WGldHnvckBu\XSqb3SsJGlEPTBiPTCwMlA2PyEQvF2u MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
CD34+ NHrkUGZHfW6ldHnvckBie3OjeR?= M2fHXmlvcGmkaYTpc44hd2ZiSlHLNkBqdiCqdX3hckBETDN2KzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEWSTz3t[YRq[XSnZDDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTBiPTCwMlA4OSEQvF2u MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7Mke0NlMoRjJ4OUK3OFI{RC:jPh?=
TF1 NGC2eJVHfW6ldHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKEmOND3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiVF[xJINmdGy|LDDJR|UxKD1iMD6wPEDPxE1w Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7M{S0OVcoRjF4OUO0OFU4RC:jPh?=
T-cells NEX4Om5HfW6ldHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKGGubH;n[Y5q[yClZXzsd{1{fGmvdXzheIVlKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gWEBk\WyuczDifUBucXinZDDsfY1xcG:leYTlJJJm[WO2aX;uJI1mfGixZDygTWM2OCB;IECuNFg4KM7:TT6= MoDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
TF1 NIXGXmtHfW6ldHnvckBie3OjeR?= NEXKdG4zOCCvaX7z Moe1TY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMheHKrb4KgeI8hTVCRLXnu[JVkfGmxbjDt[YF{fXKnZDDh[pRmeiB|MDD0c{A1PSCvaX7zMEBGSzVyIE2gNE4xQTNizszNMi=> NYf3U3VHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVgxQDRpPkKyOlk5ODh2PD;hQi=>
TF1 MmrISpVv[3Srb36gZZN{[Xl? NHL2[GozOCCvaX7z MmrNTY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJyIH3pcpMh\m:ubH;3[YQh[nliSVy2JINp[WyuZX7n[UBnd3JiM{CgcYlveyxiRVO1NEA:KDBwMEmzJO69VS5? NWfkRXJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
PBMC M4nscmZ2dmO2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKEqDS{GgbY4hcHWvYX6gVGJOSyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNNTZvaX7keYNm\CCPQ2CxJJNm[3KndHnvckwhUUN3MDC9JFAvODl3IN88UU4> M{nUSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUK3OFI{Lz5{NkmyO|QzOzxxYU6=
TF1 M2TFU2Z2dmO2aX;uJIF{e2G7 NH;wOYgzKGi{cx?= NGfPWlBKdmirYnn0bY9vKG:oIFrBT|IhcW5iR13DV2Yue3SrbYXsZZRm\CCqdX3hckBVTjFiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YhW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliR13DV2Yhe3SrbYXsZZRqd25iZn;yJFUxKG2rboOgZpkhTkGFUzDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkC5OUDPxE1w NIS3O409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNFM2QSd-MkexN|A{PTl:L3G+
TF1 MWHGeY5kfGmxbjDhd5NigQ>? MlntTY5pcWKrdHnvckBw\iCMQVuyJIlvKEWSTz3zeIlufWyjdHXkJIh2dWGwIGTGNUBk\WyuczDlfJBz\XO|aX7nJJN1[WKueTDpcpRm\3KjdHXkJIJmfGFvbHHjeIFu[XOnIILldI9zfGW{IHflcoUhfW6mZYKgZ49vfHKxbDDv[kBUXEGWNTDy[ZNxd26|ZTDlcIVu\W62czDpckBqdnSncn\ldo9vKHKnZ4XsZZRwenliZnHjeI9zKDFiZ3Xu[UBxem:vb4TldkBjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkGwO{DPxE1w NFjM[4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1OlE{Pid-MkmxOVYyOzZ:L3G+
Sf9 MW\GeY5kfGmxbjDhd5NigQ>? NWHnWHN[UW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJIh2dWGwIFrBT|Eh[2G2YXz5eIlkKGSxbXHpckBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JGVNUVODLDDJR|UxKD1iMD6xNUDPxE1w M3jjfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUC1O|EyLz5{MUGwOVcyOTxxYU6=
T-cells NWTSTXYxTnWwY4Tpc44h[XO|YYm= NYm5O2s6UW6qaXLpeIlwdiCxZjDhcIxw\2WwaXOgZ4VtdHNvc4TpcZVt[XSnZDDwdo9tcW[ncnH0bY9vKGmwIH3veZNmKFRiY3XscJMh[nlibXn4[YQhdHmvcHjvZ5l1\SC{ZXHjeIlwdiCvZYToc4QtKEmFNUCgQUAxNjFzNTFOwG0v M1m2c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
ME180 NH7WUZZHfW6ldHnvckBie3OjeR?= Mn3lTY5pcWKrdHnvckBw\iCMQVuxJIlvKEmONj3zeIlufWyjdHXkJIh2dWGwIF3FNVgxKGOnbHzzJIV5eHKnc4Ppcoche3SjYnz5JIlvfGWpcnH0[YQh[mW2YT3sZYN1[W2jc3WgdoVxd3K2ZYKg[4Vv\SC3bnTldkBkd262cn;sJI9nKHOrcz3pcoR2[2mkbHWg[YxmdWWwdDDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjF{NDFOwG0v MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF3NkGzOkc,OjlzNU[xN|Y9N2F-
CTLL-2 M1q4SGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoW1O|IhcHK| NHHqdoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlNNTJvc4TpcZVt[XSnZDDtc5V{\SCFVFzMMVIh[2WubIOg[ZhxemW|c3nu[{BLSUtzL1rBT|Mh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNE4yOzJizszNMi=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
HT2 MYjGeY5kfGmxbjDhd5NigQ>? M1TiXWlvcGmkaYTpc44hd2ZiSlHLN{BqdiCvb4Xz[UBJXDJiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2WubDDndo94fGhuIFnDOVAhRSByLkG1OkDPxE1w M4rDVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
DND/L12 NFf5VmRHfW6ldHnvckBie3OjeR?= MVezNEBucW6| NEHibphKdmirYnn0bY9vKG:oIFrBT|MhcW5iaIXtZY4hTE6GL1yxNkBk\WyuczDh[pRmeiB|MDDtbY5{KGK7IHz1Z4ln\XKjc3WgZZN{[XliaX6gdJJme2WwY3Wgc4YhcHWvYX6gd4VzfW1iYXzieY1qdixiSVO5NEA:KDBwMU[g{txONg>? MmTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
T-cells NInFfW9HfW6ldHnvckBie3OjeR?= Mm\wTY5pcWKrdHnvckBw\iCMQVuyM|EhcW5iaIXtZY4hXCClZXzsd{BmgHC{ZYPzbY5oKEOGMzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFnGUodidW2jLYP0bY12dGG2ZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vNCCLQ{WwJF0hOC5zNzFOwG0v NXS3cJFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OFA3PDhpPkKzOVQxPjR6PD;hQi=>
insect cells MYLGeY5kfGmxbjDhd5NigQ>? NH;K[YtKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgWJlsOiCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW|aX7nJFM2KHWPIFHUVEwhUUN3MDC9JFAvOTd4IN88UU4> NYfHWZFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOVU3ODVpPkKxNVU2PjB3PD;hQi=>
Ba/F3 NWnPflhVTnWwY4Tpc44h[XO|YYm= NIOySFQ3OCCvaX7z NIjXbm1KdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDKRWszKGW6cILld5Nm\CCrbjDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNVSVR3IIDoc5NxcG:{eXzheIlwdiCjZoTldkA3OCCvaX7zJIJ6KEGucHjhV4Nz\WWwIHHzd4F6NCCLQ{WwJF0hOC5{NkWg{txONg>? NHfhOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC4O|c2OCd-MkKwPFc4PTB:L3G+
TF1 M3yzd2Z2dmO2aX;uJIF{e2G7 MnzZTY5pcWKrdHnvckBw\iCMQVuyJIlvKGi3bXHuJHRHOSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBk\WyuIHfyc5d1cCxiSVO1NEA:KDBwMke1NUDPxE1w MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5MUG4NEc,Ojd5N{GxPFA9N2F-
CD34+ NVnLXVhwTnWwY4Tpc44h[XO|YYm= MV:0OUBucW6| NV\lOZk{UW6qaXLpeIlwdiCxZjDKRWszKGixbX;kbY1meiCrbjDoeY1idiCFREO0L{Bk\WyuczDzdIls\WRiaX70c{BpfW2jbjD3bI9t\SCkbH;v[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVRVy2rbnT1Z4VlKFOWQWStOUBxcG:|cHjvdplt[XSrb36gdJJmcW6ldXLheIVlKG[xcjC0OUBucW6|IH\vcIxwf2WmIHL5JGVRVyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAyPSCvaX7zJIJ6KE[DQ2OgZY5idHm|aYOsJGlEPTBiPTCwMlMxOiEQvF2u Mme5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1N|MoRjJ2NEG3OVM{RC:jPh?=
A2780 MoTjSpVv[3Srb36gZZN{[Xl? NX\ZOI9EUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= NGTpV4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW5N|E5Oid-MUS1PVMyQDJ:L3G+
A2780 MXLGeY5kfGmxbjDhd5NigQ>? NEWxWXFKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBPWE1icHjvd5Bpd3K7bHH0bY9vKGG2IITodlE6QSCrbjDoeY1idiCDMke4NEBk\Wyucx?= NHTjeoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGwOVcyOSd-MkGxNFU4OTF:L3G+
A2780 MV;GeY5kfGmxbjDhd5NigQ>? MVTJcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd4MkKzPEc,OTl5NkKyN|g9N2F-
A2780 Mkm4SpVv[3Srb36gZZN{[Xl? NEWxeGtKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBPWE1icHjvd5Bpd3K7bHH0bY9vKGG2IITodlE6QSCrbjDoeY1idiCDMke4NEBk\Wyucx?= M3i2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNE[wPFQzLz5|MES2NFg1OjxxYU6=
A2780 M3H3bmZ2dmO2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? NUPpe4x5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVkzOTRpPkKzOlU6OjF2PD;hQi=>
A2780 MnjRSpVv[3Srb36gZZN{[Xl? NVGz[VF2UW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= M1nEfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUO0OFU4Lz5zNkmzOFQ2PzxxYU6=
A2780 NWe4[VR6TnWwY4Tpc44h[XO|YYm= NX3HdW81UW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= M{nqN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{eyOlU{Lz5{NkO3NlY2OzxxYU6=
A2780 NFzWTpBHfW6ldHnvckBie3OjeR?= NV3pclExUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO= NUjVXJNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPFc4PTBpPkKyNFg4PzVyPD;hQi=>
A2780 MmP5SpVv[3Srb36gZZN{[Xl? M3rMS2lvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJG5RVSCyaH;zdIhwenmuYYTpc44h[XRidHjyNVk6KGmwIHj1cYFvKEF{N{iwJINmdGy| NWr2dnp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN|k2PzVpPkOwNVM6PTd3PD;hQi=>
A2780 M2W2UWZ2dmO2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGOmaz3t[YRq[XSnZDDOVG0heGixc4Doc5J6dGG2aX;uJIF1KHSqckG5PUBqdiCqdX3hckBCOjd6MDDj[Yxtew>? M1nz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{exNVgxLz5{N{e3NVE5ODxxYU6=
YT M3HzOWZ2dmO2aX;uJIF{e2G7 NHHOSZA{OCCwZz;tcC=> NYLF[GRrUW6qaXLpeIlwdiCxZjDJUFIucW6mdXPl[EBLSUt|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiC\VDDj[YxteyCjdDCzNEBv\y:vbDDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV7M{G4Nkc,OTR3OUOxPFI9N2F-
YT MXXGeY5kfGmxbjDhd5NigQ>? NGn2TFE{OCCwZz;tcC=> MlLtTY5pcWKrdHnvckBw\iCLTEKtbY5lfWOnZDDTWGFVPUFicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFmWIHPlcIx{KGG2IEOwJI5oN22uIHL5JIludXWwb3Lsc5R1cW6pIHHuZYx6e2m| Mn\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OUOxPFIoRjF2NUmzNVgzRC:jPh?=
YT MULGeY5kfGmxbjDhd5NigQ>? MUezNEBv\y:vbB?= M2fwfWlvcGmkaYTpc44hd2ZiSVyyMYlv\HWlZXSgV3RCXDWEIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiC\VDDj[YxteyCjdDCzNEBv\y:vbDDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrcx?= M4TtfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmzNVgzLz5zNEW5N|E5OjxxYU6=
NK M171PGludXWwb4P1dJBz\XO|aY\lJIF{e2G7 MYGxJJRwKDVibXevb4c> MlLlOEB4\WWtcx?= NUPl[XM5UW2vdX7vd5VxeHKnc4PpeoUh[WO2aY\peJkhcW5ibnHpeoUh[3mwb33vcId2eyCvb37r[Zkh[XO|ZYPz[YQh[XNiZX\m[YN1KG:wIFPEN{1ETDF4KzDOT{Bk\WyuczDheEAyKHSxIEWgcYcwc2duIIDvJIZweiB2IIfl[Yt{ NYPWdos1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS1PVMyQDJpPkG0OVk{OTh{PD;hQi=>
T-cells NEXSbJlHfW6ldHnvckBie3OjeR?= MVS1JJRwKDVyMDDuUS=> M1rMbFEhcHJ? MXLJcohq[mm2aX;uJI9nKEmOMj3pcoR2[2WmIGP0ZZQ2KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBETDRtIGSgZ4VtdHNiYYSgOUB1dyB3MECgcm0h[W[2ZYKgNUBpeiCkeTDX[ZN1\XKwIHLsc5Q> M1vFSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEWzO|U3Lz5zOUC1N|c2PjxxYU6=
SUM149PT M{\XOGZ2dmO2aX;uJIF{e2G7 NH3YS|g{KHWP M3\PZVE3KGi{cx?= NHHOOHFKdmS3Y4Tpc44hd2ZiUGTQUlYhcW5iaIXtZY4hW1WPMUS5VHQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiMzD1UUBi\nSncjCxOkBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrczDpckBxemW|ZX7j[UBw\iCyZYL2ZY5i\GG2ZR?= NEC0c2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3PFEyOid-MkS5O|gyOTJ:L3G+
Hs578T Mlr2SpVv[3Srb36gZZN{[Xl? MVKzJJVO MlW2NVYhcHK| NVfu[JNkUW6mdXP0bY9vKG:oIGDUVG43KGmwIHj1cYFvKEi|NUe4WEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCB|IIXNJIFnfGW{IEG2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m|IHnuJJBz\XOnbnPlJI9nKHCnco\hcoFl[XSn M{LLWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe4NVEzLz5{NEm3PFEyOjxxYU6=
T-cells NIK0UlBHfW6ldHnvckBie3OjeR?= MnfrOVAhfG9iM{CwJI5O MWixJIhz NU\3N5BJUW6qaXLpeIlwdiCxZjDKRWsyN0qDS{OgbY4hcHWvYX6gR2Q1KHCxc3n0bZZmKFRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBKVDRvc4TpcZVt[XSnZDDTWGFVPiCyaH;zdIhwenmuYYTpc44h[XRiNUCgeI8hOzByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDJUE01KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= NGH5WmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1NlA3QCd-Mkm4OVIxPjh:L3G+
T-cells MU\GeY5kfGmxbjDhd5NigQ>? MmXhOVAhfG9iM{CwJI5O MWmxJIhz M3u1b2lvcGmkaYTpc44hd2ZiSlHLNU9LSUt|IHnuJIh2dWGwIFPEOEBxd3OrdHn2[UBVKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTWwzNXO2aX31cIF1\WRiU2TBWFUheGixc4Doc5J6dGG2aX;uJIF1KFS7cj22PVUhemW|aXT1[UBifCB3MDD0c{A{ODBibl2gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnMMVIhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3MkC2PEc,Ojl6NUKwOlg9N2F-
T-cells MYnGeY5kfGmxbjDhd5NigQ>? NUX4NYRWRjNyMDDuUS=> NW[3Wmp7OSCqch?= Mor3TY5pcWKrdHnvckBw\iCMQVuxM2pCUzJxVGnLNkBqdiCqdX3hckBETDRicH;zbZRqfmViVDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmONj3zeIlufWyjdHXkJHNVSVR|IIDoc5NxcG:{eXzheIlwdiCjdDC+N|AxKG6PIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCLTD22JJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NX3xdJRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVIxPjhpPkK5PFUzODZ6PD;hQi=>
TALL-1 NXW4e|NxTnWwY4Tpc44h[XO|YYm= MWexJJVO NVrwdItXOyCqcoO= MWTJcohq[mm2aX;uJI9nKEqDS{OgbY4hcHWvYX6gWGFNVC1zIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUUxvMjDpcoR2[2WmIGPURXQ2KHCqb4PwbI9zgWyjdHnvckBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgN{BpenNiZn;scI94\WRiYomgTWwuOiCrbnT1Z5Rqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCrbX31co9jdG:2dHnu[y=> NIr3OFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BA/F3 NFvJfIdHfW6ldHnvckBie3OjeR?= NVz1OFN[OzByIH7N NFL2fGM{KGi{cx?= M1XVPWlvcGmkaYTpc44hd2ZiSlHLN{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHH0JFMxOCCwTTDh[pRmeiB|IHjyd{BjgSCrbX31co9jdG:2dHnu[{BidmGueYPpdy=> M4T3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
OCL-AML5 NXnLNW85TnWwY4Tpc44h[XO|YYm= M3fFWlEhfU1? NH\kdYY{KGi{cx?= MYHJcohq[mm2aX;uJI9nKEqDS{KgbY4hcHWvYX6gU2NNNUGPTEWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCJTT3DV2YhcW6mdXPl[EBUXEGWNTDwbI9{eGixconsZZRqd25iYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KEePLVPTSkBqdmS3Y4Tpc44hdWWjc4Xy[YQh[W[2ZYKgN|AhdWmwczDifUBqdW23bn;icI91fGmwZx?= M3rlPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BA/F3 MoXsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M4PKeFczKGi{cx?= NXy3dHBOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKFSHTD3KRWs{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzKGeubzDhd5NigQ>? NFvyTYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BA/F3 NI\RcHdHfW6ldHnvckBie3OjeR?= NWnCSnNQOSC3TR?= MWGzJIhzew>? NWP0T5RnUW6qaXLpeIlwdiCxZjDKRWs{KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy|IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB|IHjyd{Bnd2yub4fl[EBjgSCydXzs[I94diC5aYToJJN1emWydHH2bYRqdiCkZXHkd{BjgSCrbX31co9jdG:2dHnu[{BidmGueYPpdy=> M4WxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
Huh7 MmT5SpVv[3Srb36gZZN{[Xl? Ml7YNVAhfU1? NELa[mQ{OCCvaX7z MmLqTY5pcWKrdHnvckBw\iCWeXuyJIlvKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJGlHVmGucHjhOU1qdmS3Y3XkJHNVSVR|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCycnWtbY5kfWKjdHXkJIZweiB|MDDtbY5{KGKnZn;y[UBKTk6jbIDoZVUhe3SrbYXsZZRqd25iZn;yJFMxKG2rboOgcYlveyCkeTDpcY12dm:kbH;0eIlv\w>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
Huh7 NIXjN45HfW6ldHnvckBie3OjeR?= Ml\BNVAhfU1? NYfnVZBWOzBibXnudy=> NYH5fZE1UW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKGKjc3HsJIxmfmWuIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBi\nSncjCzNEBucW6|IHL5JIludXWwb3Lsc5R1cW6p NWnzbXJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN|EyPTlpPkK2NlMyOTV7PD;hQi=>
Huh7 MV;GeY5kfGmxbjDhd5NigQ>? NHjQV5UyKHWP Ml\vN|AhdWmwcx?= NWrpbJpyUW6qaXLpeIlwdiCxZjDUfYszKGmwIHj1cYFvKEi3aEegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEmITnHsdIhiPS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEAyKHWPIIDy[U1qdmO3YnH0[YQh\m:{IEOwJI1qdnNiYnXmc5JmKEmITnHsdIhiPSC|dHnteYxifGmxbjDmc5IhOzBibXnud{BucW6|IHL5JIludXWwb3Lsc5R1cW6p MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ|MUG1PUc,OjZ{M{GxOVk9N2F-
アッセイ
Methods Test Index PMID
Western blot JAK3 / STAT5 / p-STAT5 ; LMP1 / EBNA1 / BZLF1 ; JAK3 / p-JAK3 / STAT3 27732937 26082451
Growth inhibition assay Cell number 27732937
体内試験 Tofacitinib citrate decrease a delayed-type hyper-sensitivity response and extended cardiac allograft survival in murine models. Furthermore, Tofacitinib citrate treatment of ex-vivo-expanded erythroid progenitors from JAK2V617F-positive PV patients results in specific, antiproliferative (IC50 = 0.2 μM) and pro-apoptotic activity. In contrast, expanded progenitors from healthy controls are less sensitive to Tofacitinib citrate in proliferation (IC50 > 1.0 μM), and apoptosis assays.[2] During 2 weeks of Tofacitinib citrate dosing at 10 and 30 mg/kg/d, a significant, time-dependent decrease in NK cell numbers relative to vehicle treatment is observed. Effector memory CD8+ cell numbers in the Tofacitinib citrate-treated group are 55% less than those observed in animals treated with vehicle.[3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

  • Enzyme assays:

    The JAK1, JAK2, and JAK3 kinase assays utilize a protein expressed in baculovirus-infected SF9 cells (a fusion protein of GST and the catalytic domain of human JAK enzyme) purified by affinity chromatography on glutathione−Sepharose. The substrate for the reaction is polyglutamic acid-tyrosine [PGT (4:1)], coated onto Nunc Maxi Sorp plates at 100 μg/mL overnight at 37 °C. The plates are washed three times, and JAK enzyme is added to the wells, which contained 100 μL of kinase buffer (50 mM HEPES, pH 7.3, 125 mM NaCl, 24 mM MgCl2) + ATP + 1 mM sodium orthovanadate). For Tofacitinib citrate, it is also added for kinase assay at different doses. After incubation at room temperature for 30 min, the plates are washed three times. The level of phosphorylated tyrosine in a given well is determined by standard ELISA assay utilizing an anti-phosphotyrosine antibody.

細胞試験:

[2]

  • 細胞株:FDCP-EpoR JAK2WT and JAK2V617F cell lines
  • 濃度: 0-4 μM
  • 反応時間:72 hours
  • 実験の流れ:

    Determination of growth inhibition by Tofacitinib citrate is performed using identical culture conditions for both FDCP-EpoR JAK2WT and JAK2V617F cell lines. Briefly, 1 × 105 cells/mL are cultured in 96-well flat-bottom plates at 37 °C in a humidified 5% CO2 atmosphere using RPMI 1640 supplemented with 1.25% FCS, and 5% WEHI supernatant. Decreased FCS concentration is necessary to prevent binding between Tofacitinib citrate and serum proteins. Growth inhibition assays are terminated by addition of 20 μL CellTiter96 One Solution Reagent. Flat-bottom plates are incubated for an additional 3 hours for MTT assay. Absorbance is determined at 595 nm on a BioTek Synergy-HT microplate reader. Results are the average standard deviation of three independent determinations.

動物試験:

[2]

  • 動物モデル:Mauritius-origin adult cynomolgus monkeys
  • 投薬量:10, 30 mg/kg/d
  • 投与方法:Oral gavage

溶解度 (25°C)

体外

体内

左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
0.5% methylcellulose
混合させたのち直ちに使用することを推奨します。

30 mg/mL

化学情報

分子量 504.49
化学式

C16H20N6O.C6H8O7

CAS No. 540737-29-9
Storage 3年 -20°C
2年 -80°C in solvent
Smiles CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05082428 Active not recruiting -- Ulcerative Colitis Pfizer May 30 2022 --
NCT04768504 Recruiting Drug: Tofacitinib 10 mg Immune-Mediated Colitis Khashayar Esfahani|Sir Mortimer B. Davis - Jewish General Hospital March 22 2022 Phase 2
NCT05087589 Recruiting Drug: Tofacitinib Primary Sjögren''s Syndrome Peking University People''s Hospital November 20 2021 Phase 2
NCT04624230 Recruiting Drug: tofacitinib Ulcerative Colitis Pfizer August 12 2021 Phase 3
NCT04496960 Recruiting Drug: tofacitinib|Other: Placebo Sjogren''s Syndrome National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) May 18 2021 Phase 1|Phase 2
NCT04424303 Recruiting Drug: Tofacitinib Ulcerative Colitis Pfizer December 4 2020 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
What is the difference between the two products (S5001, S2789)?

回答
Tofacitinib (S2789) is the base form of Tofacitinib citrate (S5001). The biological activity of these two compound are same. S5001 is better than S2789 for Oral gavage.

Tags: Tofacitinib (CP-690550) Citrateを買う | Tofacitinib (CP-690550) Citrate ic50 | Tofacitinib (CP-690550) Citrate供給者 | Tofacitinib (CP-690550) Citrateを購入する | Tofacitinib (CP-690550) Citrate費用 | Tofacitinib (CP-690550) Citrate生産者 | オーダーTofacitinib (CP-690550) Citrate | Tofacitinib (CP-690550) Citrate化学構造 | Tofacitinib (CP-690550) Citrate分子量 | Tofacitinib (CP-690550) Citrate代理店